The Journal of Organic Chemistry
Page 6 of 7
125.4, 125.3, 124.6, 122.1, 110.2, 30.4; HRMS (ESI): [M+H]+
δ 161.8, 152.9, 149.6, 144.9, 140.6, 132.9, 125.7, 125.5, 120.1,
118.9, 111.0, 61.1, 14.4; HRMS (ESI): [M+H]+ calcd. for
C13H11N3O3: m/z = 258.0873; found, 258.0871.
1
2
3
4
5
6
7
8
calcd. for C12H9N3O2: m/z = 228.0768; found, 228.0764.
5-phenyl-2-(1H-pyrazol-1-yl)benzo[d]oxazole (3j). white
solid (125 mg, 96%); mp 130-132 °C; 1H NMR (600 MHz, CDCl3):
δ 8.40 (d, J = 2.0 Hz, 1H), 7.88 (d, J = 11.6 Hz, 2H), 7.61 (d, J = 6.9
Hz, 3H), 7.57-7.53 (m, 1H), 7.47 (dd, J = 11.1, 3.9 Hz, 2H), 7.37
(dd, J = 10.9, 4.1 Hz, 1H), 6.58 (d, J = 1.7 Hz, 1H). 13C {1H} NMR
(150 MHz, CDCl3): δ 154.3, 149.0, 144.7, 141.5, 140.9, 139.4,
130.0, 129.0, 127.6, 124.4, 118.2, 110.8, 109.9; HRMS (ESI):
[M+H]+ calcd. for C16H11N3O: m/z = 262.0975; found, 262.0970.
5-nitro-2-(1H-pyrazol-1-yl)benzo[d]oxazole (3k). white solid
(56 mg, 49%); mp 183-185 °C; 1H NMR (600 MHz, CDCl3): δ
8.54 (d, J = 2.0 Hz, 1H), 8.40 (d, J = 2.7 Hz, 1H), 8.29 (dd, J = 8.9,
2.1 Hz, 1H), 7.92 (s, 1H), 7.68 (d, J = 8.9 Hz, 1H), 6.64-6.62 (m,
1H). 13C {1H} NMR (150 MHz, CDCl3): δ 155.9, 152.9, 146.0,
145.6, 141.5, 130.5, 121.0, 115.9, 111.1, 110.7; HRMS (ESI):
[M+H]+ calcd. for C10H6N4O3: m/z = 231.0513; found, 231.0509.
5-(2-(benzo[d]oxazol-5-yl)-1,1,1,3,3,3-hexafluoropropan-2-
yl)-2-(1H-pyrazol-1-yl)benzo[d]oxazole (3l-1). white solid (108
mg, 48%); mp 156-159 °C; 1H NMR (600 MHz, CDCl3): δ 8.37 (d,
J = 2.7 Hz, 1H), 8.15 (s, 1H), 7.96 (s, 1H), 7.89 (s, 1H), 7.81 (s,
1H), 7.57 (t, J = 8.4 Hz, 2H), 7.40 (d, J = 8.8 Hz, 1H), 7.35 (d, J =
8.7 Hz, 1H), 6.59 (dd, J = 2.5 Hz, 1.3, 1H). 13C {1H} NMR (150
MHz, CDCl3): δ 154.8, 153.7, 150.1, 149.5, 145.0, 141.0, 140.2,
131.1, 130.3, 130.2, 128.0, 127.1, 124.3 (d, J = 285.2 Hz), 123.2,
122.1, 110.9, 110.6, 110.2, 65.0 (p, J = 25.2 Hz); HRMS (ESI):
[M+H]+ calcd. for C20H10F6N4O2: m/z = 453.0781; found,
453.0771.
1-(benzo[d]oxazol-2-yl)-1H-pyrazole-4-carbonitrile
(3q).
white solid (44 mg, 42%); mp 188-190 °C; 1H NMR (600 MHz,
CDCl3): δ 8.81 (s, 1H), 8.13 (s, 1H), 7.77-7.71 (m, 1H), 7.64-7.59
(m, 1H), 7.45-7.40 (m, 2H). 13C {1H} NMR (150 MHz, CDCl3): δ
152.1, 149.7, 145.4, 140.3, 134.9, 126.1, 126.0, 120.5, 111.7,
111.2, 97.0; HRMS (ESI): [M+H]+ calcd. for C11H6N4O: m/z =
211.0614; found, 211.0613
2-(1H-1,2,4-triazol-1-yl)benzo[d]oxazole (3t). white solid (47
mg, 50%); mp 127-130 °C; 1H NMR (600 MHz, CDCl3): δ 9.05 (s,
1H), 8.21 (s, 1H), 7.73 (dd, J = 5.3, 1.8 Hz, 1H), 7.60 (dd, J = 5.1,
1.5 Hz, 1H), 7.44-7.37 (m, 2H). 13C {1H} NMR (150 MHz, CDCl3):
δ 154.2, 151.2, 149.5, 144.1, 140.2, 125.9, 125.8, 120.4, 111.1;
HRMS (ESI): [M+H]+ calcd. for C9H6N4O: m/z = 187.0614; found,
187.0612
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2-(1H-1,2,3-triazol-1-yl)benzo[d]oxazole, 2-(2H-1,2,3-triazol-
2-yl)benzo[d]oxazole (3u). white solid (60 mg, 64%); mp 84-
1
88 °C; H NMR (600 MHz, CDCl3): δ 8.49 (d, J = 1.1 Hz, 0.86H),
8.03 (s, 2 H), 7.90 (s, 0.86H), 7.79-7.75 (m, 1.86H), 7.65-7.61 (m,
1.86H), 7.44-7.40 (m, 3.72H). 13C {1H} NMR (150 MHz, CDCl3):
δ 152.6, 151.4, 149.7, 149.6, 140.6, 140.1, 138.7, 134.6, 126.2,
126.2, 125.9, 125.9, 125.8, 123.5, 120.7, 120.5, 111.3, 111.1;
HRMS (ESI): [M+H]+ calcd. for C9H6N4O: m/z = 187.0614; found,
187.0612
ASSOCIATED CONTENT
5,5'-(perfluoropropane-2,2-diyl)bis(2-(1H-pyrazol-1-
Supporting Information
yl)benzo-[d]oxazole) (3l-2).white solid (163 mg, 63%); mp 195-
1
The Supporting Information is available free of charge on the
ACS Publications website.
197 °C; H NMR (600 MHz, CDCl3): δ 8.38 (d, J = 2.7, 2H), 7.90
(d, J = 1.1, 2H), 7.83 (s, 2H), 7.57 (d, J = 8.8, 2H), 7.35 (d, J = 8.7,
2H), 6.61-6.57 (m, 2H). 13C {1H} NMR (150 MHz, CDCl3): δ 154.8,
149.5, 145.1, 141.0, 131.0, 130.2, 127.1, 124.3 (d, J = 285.3 Hz),
122.1, 110.6, 110.4, 65.0 (p, J = 25.7 Hz); HRMS (ESI): [M+H]+
calcd. for C23H12F6N6O2: m/z = 519.0999; found, 519.0987.
2-(3-methyl-1H-pyrazol-1-yl)benzo[d]oxazole (3m). white
solid (55 mg, 55%); mp 100-102 °C; the regioselectivity is sup-
ported by an X-ray crystallographic structure determination,
see Supporting Information; 1H NMR (600 MHz, CDCl3): δ 8.25
(d, J = 2.6 Hz, 1H), 7.64 (d, J = 7.4 Hz, 1H), 7.54 (d, J = 7.9 Hz, 1H),
7.33 (t, J = 7.4 Hz, 1H), 7.29 (td, J = 7.9, 1.1 Hz, 1H), 6.35 (d, J =
2.7 Hz, 1H), 2.42 (s, 3H). 13C {1H} NMR (150 MHz, CDCl3): δ
154.6, 153.9, 149.4, 141.0, 130.5, 125.3, 124.6, 119.5, 110.7,
110.3, 13.9; HRMS (ESI): [M+H]+ calcd. for C11H9N3O: m/z =
200.0818; found, 200.0816.
2-(4-chloro-1H-pyrazol-1-yl)benzo[d]oxazole (3n). white
solid (70 mg, 64%); mp 116-118 °C; 1H NMR (600 MHz, CDCl3):
δ 8.36 (d, J = 0.4 Hz, 1H), 7.80 (s, 1H), 7.70-7.67 (m, 1H), 7.57
(dd, J = 7.4, 1.5 Hz, 1H), 7.40-7.34 (m, 2H). 13C {1H} NMR (150
MHz, CDCl3): δ 153.0, 149.5, 143.3, 140.6, 127.4, 125.6, 125.2,
119.9, 115.1, 110.9; HRMS (ESI): [M+H]+ calcd. for C10H6ClN3O:
m/z = 220.0272; found, 220.0271.
2-(4-bromo-1H-pyrazol-1-yl)benzo[d]oxazole (3o). white
solid (85 mg, 65%); mp 115-117 °C; 1H NMR (600 MHz, CDCl3):
δ 8.40 (d, J = 2.6 Hz, 1H), 7.82 (d, J = 2.2 Hz, 1H), 7.68 (dd, J = 7.2,
1.4 Hz, 1H), 7.60-7.53 (m, 1H), 7.41-7.32 (m, 2H). 13C {1H} NMR
(150 MHz, CDCl3) δ: 152.9, 149.5, 145.2, 140.7, 129.7, 125.6,
125.3, 120.0, 110.9, 98.6; HRMS (ESI): [M+H]+ calcd. for
C10H6BrN3O: m/z = 263.9767; found, 263.9766.
ethyl 1-(benzo[d]oxazol-2-yl)-1H-pyrazole-4-carboxylate (3p).
white solid (95 mg, 74%); mp 132-135 °C; 1H NMR (600 MHz,
CDCl3): δ 8.84 (d, J = 1.2 Hz, 1H), 8.21 (s, 1H), 7.70 (d, J = 7.2 Hz,
1H), 7.57 (d, J = 7.8 Hz, 1H), 7.39-7.36 (m, 2H), 4.35 (q, J = 7.2
Hz, 2H), 1.37 (t, J = 7.2 Hz, 3H). 13C {1H} NMR (150 MHz, CDCl3):
Experimental details, analytical data, mass spectrum, cyclic
voltammogram, and NMR spectra (PDF)
AUTHOR INFORMATION
Corresponding Author
* E-mail: lqchem@163.com (Q. Liu); xqyu@scu.edu.cn (X.-
Q.Y.).
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENT
Financial support for this research from Start-up Fund of
Chengdu University (No. 2081918024), Sichuan Science Tech-
nology Program (No. 2018JY0222) and China Scholarship
Council (No. 201808510023) is gratefully acknowledged.
REFERENCES
(1) (a) Sheng, C.; Xu, H.; Wang, W.; Cao, Y.; Dong, G.; Wang, S.; Che,
X.; Ji, H.; Miao, Z.; Yao, J.; Zhang, W. Design, synthesis and antifungal
activity of isosteric analogues of benzoheterocyclic N-
myristoyltransferase inhibitors. Eur. J. Med. Chem. 2010, 45, 3531.
(b) Jauhari, P. K.; Bhavani, A.; Varalwar, S.; Singhal, K.; Raj, P. Syn-
thesis of some novel 2-substituted benzoxazoles as anticancer, an-
tifungal, and antimicrobial agents. Medicinal Chemistry Research
2008, 17, 412. (c) Feng, H.; Ma, W.; Cui, Z.-K.; Liu, X.; Gu, J.; Lin, S.;
Zhuang, Q. J. Mater. Chem. A. 2017, 5, 8705.
(2) Zhang, M. Advances in the Direct Amination of Azole C–H
Bonds. Synthesis, 2011, 21, 3408.
(3) (a) Joseph, J.; Kim, J. Y.; Chang, S. A Metal-Free Route to 2-Ami-
nooxazoles by Taking Advantage of the Unique Ring Opening of
ACS Paragon Plus Environment